Press Program for WCLC 2013 Announced
Contact: Kristal Griffith
IASLC Director of Communications
Release: Oct. 14, 2013
Latest research in lung cancer presented at 15th WCLC
Press Conference held Monday, Oct. 28 at 12:15 pm Sydney
SYDNEY - The International Association for the Study of Lung Cancer (IASLC) will host the 15th World Conference on Lung Cancer (WCLC) Oct. 27-30, 2013 in Sydney, Australia. The press conference will be held Monday, Oct. 28 from 12:15 to 1:45 p.m. in the Bayside 101 room inside the Sydney Convention Centre. The press program will include discussions and presentations on the following topics:
IASLC Overview/Introduction by IASLC Leadership
(Moderator Jim Jett and Christine Berg)
Dr. Jim Jett, director of Clinical and Translational Research at National Jewish Health in Denver, Colorado is a renowned pulmonologist and oncologist in the field of screening. The former Editor-in-Chief of the Journal of Thoracic Oncology will give a global perspective on the current state of screening along with Dr. Christine D. Berg, adjunct research professor at George Mason University and former National Cancer Institute Lead Investigator, National Lung Screening Trial.
ID 879 The Importance of a Regimen of screening to maximize early diagnosis and treatment, Claudia Henschke, US
(Moderator Carolyn Dresler)
Dr. Carolyn Dresler, associate director for Medical and Health Sciences in the Office of Science at the FDA Center for Tobacco Products Office is a thoracic surgeon, tobacco control expert and member of the IASLC Board of Directors. She will provide a global perspective on prevention and patient care
ID 2106 Multidisciplinary smoking cessation model in a specialist oncology hospital, Marliese Alexander, Australia
ID 2113 Lung cancer risks, beliefs, and healthcare access among the underprivileged, Jean-Francois Morere, France
(Moderator Paul Bunn)
Dr. Paul A. Bunn, Jr. is a renowned medical oncologist and has been the Executive Director of the IASLC for 10 years. He will provide a global perspective on the area of treatment in lung cancer, setting the stage for perspective on the studies to be discussed.
ID 1920 Final results of CTONG 0806: a phase II trial comparing pemetrexed with gefitinib as second-line treatment of advanced non-squamous NSCLC patients with wild-type EGFR, Qing Zhou, Guangzhou, China
ID 2423 The MesoVATs study: A randomised controlled trial of video-assisted thoracoscopic partial pleurectomy compared to talc pleurodesis in patients with suspected or confirmed malignant pleural mesothelioma, Robert Rintoul, UK
ID 1424 Intergroup randomized Phase III comparison/RTOG 0617, Gregory Masters, US
ID 1661 A phase 1 dose escalation study of a new ALK inhibitor, Shirish Gadgeel, US
For press unable to attend the conference in person, please register via GoToWebinar here:
About the 15th WCLC:
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. The 2013 theme is “Next-Generation Lung Cancer Care.” More than 4,000 delegates are expected to come from more than 100 countries to discuss the latest developments in thoracic malignancy research. Attendees include surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses and allied health professionals and patients.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 3,500 lung cancer specialists in 80 countries. To learn more about IASLC please visit www.iaslc.org.